Center for Serological Testing to Improve Outcomes from Pandemic COVID-19 (STOP-COVID)

Document text

Principal Investigator: Ann Scheck McAlearney
Organization: OHIO STATE UNIVERSITY
Fiscal Year: 2022
Award: $439,659
Funding agency: National Cancer Institute

Despite robust advances in vaccine technology and therapeutic intervention, the COVID-19 pandemic continues to impact our world both through disease-associated morbidity/mortality and its influence on economic stability and growth. Cancer patients (especially those receiving active immune suppressive or altering therapy) represent a highly vulnerable population with increased risk of SARS-CoV2 breakthrough infection and severe COVID-19 despite mRNA vaccination and booster. Identifying atrisk individuals and developing more effective protective strategies against severe COVID-19 is of paramount importance. We and others have characterized antibody and T cell responses in cancer patients and identified cancer treatment (type and timing) as critically associated with subpar vaccine responses. Notably, patients being treated for hematological malignancies have greater likelihood of impaired immunity compared with those with solid tumor malignancies. Furthermore, while booster immunization can recover deficiencies in immunity in some individuals, many cancer patients continue to have deficiencies in vaccine-mediated antibody and/or T cell responses. However, most post-booster studies have not assessed long-term durable immunity and have not characterized antibody or T cell memory responses. We hypothesize that variability in the durability and memory of T cell and antibody responses following booster immunization in solid tumor and hematological cancer patients will be primarily driven by type and timing of treatment. This hypothesis is supported by our publications assessing early post-booster immune responses, however, the research proposed here will allow us to T cell and antibody memory at 1 year post booster. Furthermore, by tracking clonal T cell populations and epitope specific antibody responses within individual cancer patients, we hypothesize that can identify key parameters driving heterogeneity in SARS-CoV2 mRNA booster responses. We will address our hypotheses via in-depth immunological studies using samples collected prospectively through the COVID-19 Vaccine Study of Infections and Immune REspoNse (SIIREN) at The Ohio State University Comprehensive Cancer Center.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Acute Nasopharyngitis><Address><Antibodies><Antibody Response><Antigenic Determinants><Antigens><Archives><Assay><Automobile Driving><BSL-3 facility><BSL3 facility><Behavioral><Binding Determinants><Bio-Informatics><Bioassay><Bioinformatics><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><Blood Serum><Booster Immunization><COVID><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 exposure><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 immune response><COVID-19 infection><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 severity><COVID-19 transmission><COVID-19 vaccine><COVID-19 virus><COVID-19 virus transmission><COVID19><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 immune response><COVID19 infection><COVID19 pandemic><COVID19 public health crisis><COVID19 severity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cancer Patient><Cancer Treatment><Cancers><Characteristics><Clinical><Clinical Services><Clinical Treatment Moab><CoV disease><CoV-2><CoV2><Common Cold><Communicable Diseases><Communication><Communities><Comprehensive Cancer Center><Data><Data Analyses><Data Analysis><Department of Health and Human Services><Disease><Disorder><ELISA><Economics><Educational workshop><Enzyme-Linked Immunosorbent Assay><Epidemiology><Epitopes><Facility Accesses><Fire - disasters><Fires><Fostering><Future><Gene Expression><Generalized Growth><Genetic><Goals><Growth><Health Services><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><Heterogeneity><Household><Immune><Immune response><Immunes><Immunity><Immunochemical Immunologic><Immunologic><Immunological><Immunological response><Immunologically><Immunologics><Impairment><Individual><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Infrastructure><Investigators><Knowledge><Laboratories><Leadership><Longitudinal Studies><Maintenance><Malignant Hematologic Neoplasm><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mediating><Memory><Messenger RNA><Methodology><Molecular><Monoclonal Antibodies><Morbidity><Morbidity - disease rate><Natural History><Observation research><Observation study><Observational Study><Observational research><Ohio><Outcome><PBMC><Pathogenesis><Patients><Peripheral Blood Mononuclear Cell><Persons><Police><Population><Prevalence><Process><Psychometrics><Public Health><Publications><R-Series Research Projects><R01 Mechanism><R01 Program><RNA immunization><RNA vaccination><Reagent><Research><Research Grants><Research Personnel><Research Project Grants><Research Projects><Research Resources><Researchers><Resource Sharing><Resources><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 exposure><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 immune response><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 pathogenesis><SARS-CoV-2 severity><SARS-CoV-2 transmission><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 exposure><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Science><Scientific Publication><Secondary Immunization><Serology><Serology test><Serum><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 exposure><Severe acute respiratory syndrome coronavirus 2 immune response><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severity of illness><Solid Neoplasm><Solid Tumor><T cell response><T memory cell><T-Cells><T-Lymphocyte><Technology><Test Result><Testing><Therapeutic Intervention><Tissue Growth><Transmission><United States Department of Health and Human Services><United States Dept. of Health and Human Services><Universities><Vaccination><Vaccines><Viral><Virus><Vulnerable Populations><Work><Workshop><Wuhan coronavirus><anti-cancer therapy><anticancer therapy><biobank><biorepository><biosafety level 3 facility><booster vaccination><breakthrough infection><cancer therapy><cancer-directed therapy><cohort><complex data><corona virus disease><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 exposure><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 immune response><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 severity><coronavirus disease 2019 transmission><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease 2019 virus transmission><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><cost><data interpretation><data management><data quality><data sharing><design><designing><disease severity><driving><enzyme linked immunoassay><epidemiologic><epidemiological><exposure to COVID-19><exposure to SARS-CoV-2><exposure to SARS-CoV2><exposure to Severe acute respiratory syndrome coronavirus 2><exposure to coronavirus disease 2019><fire><first responder><hCoV19><high risk><host response><immune system response><immunogen><immunoresponse><improved><improved outcome><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><innovate><innovation><innovative><insight><intervention therapy><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><long-term study><longitudinal outcome studies><longterm study><mAbs><mRNA><mRNA immunization><mRNA vaccination><malignancy><memory T lymphocyte><mortality><nCoV2><neoplasm/cancer><novel><ontogeny><pathogen><population health><prospective><respiratory virus><response><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><serology assay><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 pathogenesis><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 transmission><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><synergism><thymus derived lymphocyte><transmission process><transmitted COVID-19><transmitted SARS-CoV-2><transmitted coronavirus disease 2019><transmitted severe acute respiratory syndrome coronavirus 2><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><vaccine response><vaccine responsiveness><vaccine study><vaccine trial><vaccine-induced response><viral microbiome><virome><virtual><vulnerable group><vulnerable people>